Formulary guidance and transparency from P&T to point of care

Market Access in Disease Modifying Agents

Posted by Jayne Hornung on Jul 23, 2015

Find me on:


An Overcrowded Arena?

In the fight to slow down disease progression in many inflammatory conditions such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, the disease modifying agents class, including therapies such as anti-TNF agents and immunomodulators, is experiencing a surge of growth. There are 15 FDA approved non-biologics and biologics that compete in the market today with an estimated 18 biosimilar or generic agents currently in trials.

The anti-TNF agents have been consistently effective in treating the signs and symptoms of diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ms disease, and Crohn’s disease, inhibiting progression of each disease. However, the landscape has evolved to include JAK inhibitors, several anti-interleukins, and the newer PDE4 inhibitors that all modify the body’s immune response.  There are several novel RA drugs, modifying drugs, and biologics and biosimilars in the pipeline, all of which will provide significant options for patients suffering from these diseases, but also crowd an already crowded market. How will your market access hold up through this growth? 

Disease Modifying Agents Market Access


Source: MMIT data, current as of July 2015.

With the anti-TNFs as extremely effective therapies, the market is exceptionally competitive for new entrants and will undergo mounting pressure as even more biosimilars are approved and launched. As this current market access snapshot reveals, coverage is complex and all brands face restrictions on some plans, even when they may be preferred. 

Amgen/AstraZeneca’s brodalumab, Eli Lilly’s ixekizumab and Johnson & Johnson’s guselkumab are all progressing through trials with a slew of other treatments right on their heels.

Staying Ahead of the Curve

What tools do you have to monitor the market landscape and the utilization management techniques being employed by health plans and PBMs?

MMIT will equip your organization with class-specific data and analytics to provide a picture of the current market and to enable you to monitor changes as they occur. MMIT’s in-house team of pharmacists structures critical data about how DMARD therapies are managed and covered from complex, narrative policies on an ongoing basis.

We help companies understand their brand’s market access and competitive position in the DMARDs marketplace and can help put your organization ahead of the curve. 

 Learn More

Topics: Specialty, Market Access